This is a fascinating compound, from its design to its MOA to its recent P2 data, though limited in volume. I place some weight on the 54 PD patients data since it is a reasonable mid size sample size to attain a starting point for stats. I don't think I have ever seen such a strong stat performance from such a small sample population, which is eye opening. The observations of rapid enrollment and low drop out rates in both trials are indicative of trial physician support and at least patient safety success.
The contradiction here is that the MOA is superbly simplistic and holistic as far as neurodegeneration is concerned but the logic of its approach gives one the initial impression that there is no way Big Pharma could have missed this approach. But BP can be blinded at times and it takes years to decades to modify their approach. This approach seems too simple, but this would not be the first such example of a simpler approach being correct since the scientific achievement is in finding how to make the simpler approach a reality. This compound's MOA helps to explain why there have been other single degenerative protein approaches which have demonstrated limited temporary success only to completely succumb in the longer term as only one degenerative protein is being controlled by the other compounds while the other degenerative proteins continue to agglomerate in the brain. This means there exists synergy between the decades long BP approaches and this one.
The alignment of all the preclinical through early to mid clinical data is consistent but in the field of neuro there are hurdles of proof in cognitive testing, which is why Parkinsons mobility is a great complement to evaluate concurrently with AD cognition. I see this as an interesting SWAG at this stage as there is compelling data but not a lot of it, otherwise the company would already be in the billions. Not many small companies, though I know of one in oncology, can offer such potential value. This compound, like the other company I reference could bring medical science revolution to the market. The benefit this company has is a shorter development timeline than the other company, more traditional trial metrics, and it has not garnered the destructive attention of large shorting entities. The timeline here now does not allow for large shorting games and the potential upside value is too significant of a risk given the low float.
All in all this is still a binary investment situation but there is a strong positive case for a potentially successful outcome in a medical field where all have failed to date, except a few very limited successes. Patenting the newly developed crystalline form of the compound for IP purposes in addition to added stability is a positive. I think, given the safety profile that will be available and the proof of the MOA post both the PD and AD trials in coming months if both trials are successful, the FDA will be receptive to an accelerated approval pathway, at least that would be logical and patient serving though it is possible there may be additional P3's in both indications required, strength of results may be the determining factor.
GLTA
Recent ANVS News
- Annovis Bio Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results • GlobeNewswire Inc. • 04/02/2024 11:30:00 AM
- US Stock Movers Before Market: Beyond Meat, eBay, First Solar, Urban Outfitters… • IH Market News • 02/28/2024 12:08:14 PM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 02/12/2024 07:00:23 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 02/01/2024 09:05:20 PM
- Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] • Edgar (US Regulatory) • 11/22/2023 09:27:49 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/21/2023 07:33:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/21/2023 07:31:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/21/2023 07:29:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/21/2023 07:27:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/08/2023 09:45:28 PM
- Annovis Bio Measures Novel Biomarkers in Plasma of Parkinson’s Patients • Business Wire • 11/02/2023 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/01/2023 04:28:35 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/01/2023 04:24:40 PM
- Annovis Bio Announces Pricing of $7.5 Million Public Offering • Business Wire • 10/31/2023 12:00:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 10/30/2023 09:27:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 09:17:25 PM
- Annovis Bio Announces Launch of Proposed Public Offering • Business Wire • 10/30/2023 08:48:00 PM
- Annovis Bio Receives Positive Recommendation to Continue Phase 2/3 Trial of Buntanetap for Alzheimer’s Disease Patients From the Independent Data and Safety Monitoring Board (DSMB) • Business Wire • 10/30/2023 08:42:00 PM
- Annovis Bio Showcases Promising Progress in Novel Drug Development at the 2023 Clinical Trials on Alzheimer's Disease Conference • Business Wire • 10/24/2023 01:13:00 PM
- Dawson James Securities Announces October Date for 8th Annual Small Cap Growth Conference • GlobeNewswire Inc. • 09/21/2023 01:35:00 PM
- Annovis Bio Announces Second Quarter 2023 Financial Results and Provides Corporate Update • Business Wire • 08/15/2023 11:20:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 08:40:20 PM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM